Browsing Tag
Oruka Therapeutics
3 posts
Oruka Therapeutics stock surges as ORKA-001 psoriasis trial success puts $1.1bn biotech strategy to the test
Oruka Therapeutics stock rallies after ORKA-001 delivers 61% psoriasis clearance. Explore its $1.1B cash position and Phase 3 growth potential.
Enliven Therapeutics appoints Kristine Ball as $895m-backed leukemia Phase 3 trial nears
Enliven Therapeutics has expanded its board and appointed a new audit committee member as it prepares to initiate a pivotal 450-patient study of relcobatinib before the end of 2026. With FDA alignment secured on the trial design and substantial cash reserves, attention is shifting towards clinical execution, competitive differentiation and eventual commercial readiness.
Oruka Therapeutics builds long-acting psoriasis case as ORKA-001 clearance deepens without redosing
ORKA-001 reaches 71.4% complete psoriasis clearance without redosing as Oruka Therapeutics advances its long-acting biologic toward Phase 3.